Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
Study in Patients With Chronic Leukemia Where Previous Therapy Failed and Who Will be Treated With Ponatinib as Second Line Therapy

previous therapy but which has not been effective. Patients will be treated with Ponatinib 30 mg in in this study. The aim of the study is to evaluate the safety and efficacy of Ponatinib as a second line

  • 0 views
  • 15 May, 2021
  • 10 locations
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib. For all options the treatment duration is for a minimum of 12 months and will be

  • 11 views
  • 24 Jan, 2021
  • 24 locations
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid

myeloid leukemia
blast crisis
cancer
ponatinib
KIT
  • 23 views
  • 26 Jan, 2021
  • 32 locations
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim

cancer
ponatinib
residual tumor
minimal residual disease
prednisone
  • 72 views
  • 03 Jul, 2021
  • 128 locations
A Study of Ponatinib With Chemotherapy in Children Teenagers and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

This study is about an anticancer drug called ponatinib which is a tyrasine kinase inhibitor given with chemotherapy to children, teenagers, and young adults up to 21 years of age with

  • 0 views
  • 22 Jul, 2021
  • 59 locations
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

The primary objective of this study is to determine in an exploratory manner the objective overall response rate to ponatinib in the treatment of patients with advanced or metastatic MTC

  • 0 views
  • 24 May, 2021
  • 1 location
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in

ponatinib
doxorubicin
blast cells
cyclophosphamide
dexamethasone
  • 102 views
  • 25 May, 2021
  • 1 location
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic

  • 0 views
  • 28 Jun, 2021
  • 7 locations
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1 FGFR2 FGFR3 FGFR4 RET KIT.

This phase II trial studies how well ponatinib hydrochloride works in treating patients with cancer that has spread to other parts of the body (metastatic), has failed previous treatment

RET
metastatic solid tumor
primary tumor
advanced malignant solid tumor
primary cancer
  • 22 views
  • 23 Jan, 2021
  • 2 locations
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

The investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a

basophils
busulfan
ponatinib
chronic phase chronic myeloid leukemia
cytarabine
  • 0 views
  • 22 Jul, 2021
  • 35 locations